StreetAlpha.app
Home › Stocks › RCKT

Rocket Pharmaceuticals, Inc. (RCKT)

Healthcare
$1.95
▼ −7.58%
LAST CLOSE · NOV 20

Rocket Pharmaceuticals develops gene therapies for rare inherited heart diseases. It last closed at $1.95 on Nov 20, down 7.58% on the day. The next earnings report for RCKT is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, RCKT reported EPS of -$0.43 on revenue of $0. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months RCKT insiders bought $34K of stock on the open market and sold $991K, according to SEC Form 4 filings.

AI Auto Pilots
Is RCKT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RCKT.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$16.2M
EPS (diluted)
−$0.15
Free cash flow
−$159.2M
Valuation
Market cap
$217.7M
111.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$95.5M
At Sep 30
Debt
$30.4M
At Sep 30
Shareholder equity
$326.7M
Shares outstanding
111.7M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From RCKT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.43
Quarter ended Sep 2026
Year ago EPS
-$0.45
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.62Dec '24Mar 2025: -$0.56Mar '25Jun 2025: -$0.62Jun '25Sep 2025: -$0.45Sep '25Dec 2025: -$0.38Dec '25Mar 2026: -$0.42Mar '26Jun 2026: $1.08Jun '26Sep 2026: -$0.43Sep '26Latest -$0.43
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How RCKT moved after its last 8 reports
Average move the session after a report ±3.7%
Nov 12, 2026After the close−3.8%
Aug 10, 2026After the close−3.9%
May 7, 2026After the close−1.1%
Feb 26, 2026After the close+10.6%
Nov 6, 2025After the close−1.9%
Aug 7, 2025After the close−7.4%
May 8, 2025After the close−0.7%
Feb 27, 2025After the close+0.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RCKTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on RCKT: 0 upgrades, 0 downgrades, 0 initiations
Chardan CapitalReiterated
Nov 20Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on RCKT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RCKT

Technical Analysis

RCKT · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 21% below its 20 day and 31% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $1.94, and the nearest resistance the Pivot at $2.02.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.8%/day
Key levels
$5.4552 week high+179.5%
$3.36200 day average+72.3%
$3.06100 day average+56.9%
$2.5650 day average+31.3%
$2.38Swing high (Oct 21)+22.1%
$2.3620 day average+21.0%
$2.10Pivot R1+7.7%
$2.02Pivot+3.6%
$1.95Last close
$1.9452 week low−0.5%
$1.87Pivot S1−4.1%
Indicators
RSI (14)30.72Weak, oversold below 30Neutral
MACD-0.13Below its signal lineBearish
Stochastic8.9Near the bottom of its rangeOversold
ADX (14)17.6No clear trend
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-163.7Oversold below −100, overbought above 100Oversold
Rate of change−18.2%Change over 10 sessionsBearish
ATR (14)$0.19Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCKT

What happened before

See how RCKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RCKT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RCKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RCKTHow many large options trades hit RCKT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RCKT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼70 buying vs 104 selling
  • ▼Held by funds -4.2 pts
  • ▼Funds holding -18
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding175193−9.3%
In funds' top 10110.0%
Held by funds86.6%90.8%−4.2 pts
New / increased18 / 5219 / 73−23.9%
Reduced / sold out67 / 3765 / 34+5.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCKT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RCKT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$34K1 buy · 1 insider
Sold$991K27 sales · 5 insiders
2026-01 bought $34K2026-02 sold $122K2026-05 sold $275K2026-08 sold $176K2026-09 sold $256K2026-11 sold $161KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Martin WilsonGeneral CounselSale677$2.18$1K
Nov 18Gaurav ShahCEOSale2,216$2.18$5K
Nov 13Martin WilsonGeneral CounselSale4,087$2.25$9K
Nov 13Gaurav ShahCEOSale3,020$2.25$7K
Nov 9Sarbani ChaudhuriSee RemarksSale4,872$2.33$11K
Nov 5Martin WilsonGeneral CounselSale53,389$2.39$128K
Every insider buy and sale for RCKT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RCKT insider trades →

From SEC Form 4 filings by RCKT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCKT is in one of them and how their past RCKT trades turned out.

RCKT in the AI portfolios
Loading…

RCKT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCKT in an article yet. Here's the latest on the wider market.

RCKT in the news

About Rocket Pharmaceuticals

Rocket Pharmaceuticals is a biotechnology company based in New York that develops gene therapies for rare inherited diseases. Its main focus is heart conditions caused by genetic mutations, such as certain forms of cardiomyopathy. The company uses modified viruses that do not cause disease to deliver working copies of genes into patients' cells. Its treatments are aimed at patients with rare conditions, and the company works with healthcare providers, payors and patient communities.

Headquarters
New York, NY